Theralase Technologies Inc. | Facebook
Market Herald logo

Find out more about this capital raise

Be the first with the news that moves the market
  • TheralaseTechnologies (TLT) has commenced a non-brokered C$2.5 million follow-on private placement equity financing
  • Up to 10,000,000 units are available to be sold to accredited investors at a price of $0.25 per unit for aggregate gross proceeds of up to $2,500,000
  • Each warrant will entitle the holder to acquire an additional common share at an exercise price of $0.35 per share for a period of 24 months following the date of closing
  • TheralaseTechnologies Inc. is a clinical-stage pharmaceutical company dedicated to the research and development of light-activated compounds and their associated drug formulations
  • Theralase Technologies Inc. opened trading at $0.27 per share

TheralaseTechnologies (TLT) has commenced a non-brokered C$2.5 million follow-on private placement equity financing.

Up to 10,000,000 units are available to be sold to accredited investors at a price of $0.25 per unit for aggregate gross proceeds of up to $2,500,000.

Each unit will consist of one common share of the company and one common share purchase warrant.

Each warrant will entitle the holder to acquire an additional common share at an exercise price of $0.35 per share for a period of 24 months following the date of closing.

The company plans to use the proceeds of the financing for a Good Laboratory Practice toxicology study for intravenous installation of Rutherrin, advancement of Phase II Non-Muscle Invasive Bladder Cancer clinical study, and working capital and general corporate purposes

Closing of the financing is subject to approval by the TSX Venture Exchange. Securities issued in the financing are subject to a statutory hold period of four months.

Closing of the financing is intended to occur on or about October 14, 2022.

Theralase Technologies Inc. is a clinical-stage pharmaceutical company dedicated to the research and development of light-activated compounds and their associated drug formulations with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses.

Theralase Technologies Inc. opened trading at $0.27 per share.


More From The Market Herald

" Voyageur (TSXV:VM) completes SmoothX testing

Voyageur Pharmaceuticals (VM) has completed the production test batch of its SmoothX product for the computerized tomography (CT) imaging market in Canada.
Aleafia Health - CEO, Tricia Symmes

" Aleafia Health (TSX:AH) completes TSX review and enters fifth province

Aleafia Health (AH) has completed the TSX delisting review and has satisfied the Toronto Stock Exchange’s requirements for continued listing.

" Alpha Cognition (TSXV:ACOG) withdraws public offering

Alpha Cognition (ACOG) has withdrawn its previously-announced marketed public offering.

" Aurwest (CSE:AWR) and Copper Star announce a non-brokered private placement

Aurwest Resources Corporation (AWR) has disclosed that Copper Star plans to complete a private placement financing.